SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.
On November 14, 2023, at 10:55 a.m. EST, Trey Martin, Chief Executive Officer (CEO) and Kevin Herde, Chief Financial Officer (CFO), will participate in a fireside chat at the Stifel Healthcare Conference, 2023, being held at the Lotte New York Palace Hotel, in New York City, NY.
On November 16, 2023, at 2:00 p.m. GMT, Trey Martin, Chief Executive Officer (CEO) and Kevin Herde, Chief Financial Officer (CFO), will participate in a fireside chat at the Jefferies London Healthcare Conference, 2023, being held at the Waldorf Hilton, in London, England.
A live webcast of the presentations will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events. An archived version of the webcasts will also be available on the Maravai website following the completion of each event.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Contact Information:
Media Contact:
Sara Michelmore
MacDougall Advisors
+1 781-235-3060
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.34 |
Daily Change: | 0.01 0.30 |
Daily Volume: | 629,380 |
Market Cap: | US$483.230M |
June 09, 2025 June 03, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load